DavidLSchiffMD

PubMed

• Proposed Response Assessment and Endpoints for Meningioma Clinical Trials: Report from the Response Assessment in Neuro-Oncology (RANO) Working Group.
  Huang, R. Y.,Bi, W. L.,Weller, M.,Kaley, T.,Blakeley, J.,Dunn, I.,Galanis, E.,Preusser, M.,McDermott, M.,Rogers, L.,Raizer, J.,Schiff, D.,Soffietti, R.,Tonn, J. C.,Vog...> ;Neuro-oncology. 2018 Aug 24
• The siren song of bevacizumab: swan song or clarion call?
  Schiff, D.,Wen, P. Y.> ;Neuro-oncology. 2018 Jan 25
• Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813.
  Chang S, Zhang P, Cairncross JG, Gilbert MR, Bahary J, Dolinskas CA, Chakravarti A, Aldape KD, Bell EH, Schiff D, Jaeckle K, Brown PD, Barger GR, Werner-Wasik M, Shih ...> ;Neuro-oncology. 2016-12-18
• Highlights from the Literature.
  Schiff D, Lawler S, Chamberlain M, Wright K, Bhat K> ;Neuro-oncology. 2016-12-01
• Molecular profiling optimizes the treatment of low-grade glioma.
  Schiff D> ;Neuro-oncology. 2016-12-01
• Culture conditions tailored to the cell of origin are critical for maintaining native properties and tumorigenicity of glioma cells.
  Ledur PF, Liu C, He H, Harris AR, Minussi DC, Zhou H, Shaffrey ME, Asthagiri A, Lopes MBS, Schiff D, Lu Y, Mandell JW, Lenz G, Zong H> ;Neuro-oncology. 2016-10-01
• Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials.
  Avila EK, Chamberlain M, Schiff D, Reijneveld JC, Armstrong TS, Ruda R, Wen PY, Weller M, Koekkoek JAF, Mittal S, Arakawa Y, Choucair A, Gonzalez-Martinez J, MacDonald...> ;Neuro-oncology. 2016-09-20
• Preradiation Chemotherapy for Adult High-risk Medulloblastoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4397).
  Moots PL, O'Neill A, Londer H, Mehta M, Blumenthal DT, Barger GR, Grunnet ML, Grossman S, Gilbert MR, Schiff D> ;Am. J. Clin. Oncol.. 2016-09-15
• Highlights from the Literature.
  Lawler S, Schiff D, Wick W, Chamberlain M, Wright K> ;Neuro-oncology. 2016-09-01
• Living in a material world: tumor-treating fields at the top of the charts.
  Schiff D, Schrag D> ;Neuro-oncology. 2016-08-01
• PCV in low-grade gliomas: benefit from old drugs in an evolving disease entity.
  Schiff D> ;Neuro-oncology. 2016-06-01
• Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in ne...
  Schiff D, Desjardins A, Cloughesy T, Mikkelsen T, Glantz M, Chamberlain MC, Reardon DA, Wen PY> ;Cancer. 2016-02-15
• Quantifying the burden of primary central nervous system malignancy.
  Schiff D> ;Neuro-oncology. 2016-01-01
• Response assessment after stereotactic body radiotherapy for spinal metastasis: a report from the SPIne response assessment in Neuro-Oncology (SPINO) group.
  Thibault I, Chang EL, Sheehan J, Ahluwalia MS, Guckenberger M, Sohn M, Ryu S, Foote M, Lo SS, Muacevic A, Soltys SG, Chao S, Gerszten P, Lis E, Yu E, Bilsky M, Fisher ...> ;Lancet Oncol.. 2015-12-01
• Evolution of brain lesions in a patient with TREX1 cerebroretinal vasculopathy.
  Dhamija R, Schiff D, Lopes MBS, Jen JC, Lin DD, Worrall BB> ;Neurology. 2015-11-03
• A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K.
  Ma DJ, Galanis E, Anderson SK, Schiff D, Kaufmann TJ, Peller PJ, Giannini C, Brown PD, Uhm JH, McGraw S, Jaeckle KA, Flynn PJ, Ligon KL, Buckner JC, Sarkaria JN> ;Neuro-oncology. 2015-09-01
• A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients.
  Lee EQ, Kaley TJ, Duda DG, Schiff D, Lassman AB, Wong ET, Mikkelsen T, Purow BW, Muzikansky A, Ancukiewicz M, Huse JT, Ramkissoon S, Drappatz J, Norden AD, Beroukhim R...> ;Clin. Cancer Res.. 2015-08-15
• Dasatinib in recurrent glioblastoma: failure as a teacher.
  Schiff D, Sarkaria J> ;Neuro-oncology. 2015-07-01
• Response assessment criteria for brain metastases: proposal from the RANO group.
  Lin NU, Lee EQ, Aoyama H, Barani IJ, Barboriak DP, Baumert BG, Bendszus M, Brown PD, Camidge DR, Chang SM, Dancey J, de Vries EGE, Gaspar LE, Harris GJ, Hodi FS, Kalka...> ;Lancet Oncol.. 2015-06-01
• Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma.
  Lee EQ, Reardon DA, Schiff D, Drappatz J, Muzikansky A, Grimm SA, Norden AD, Nayak L, Beroukhim R, Rinne ML, Chi AS, Batchelor TT, Hempfling K, McCluskey C, Smith KH, ...> ;Neuro-oncology. 2015-06-01
• Medical management of brain tumors and the sequelae of treatment.
  Schiff D, Lee EQ, Nayak L, Norden AD, Reardon DA, Wen PY> ;Neuro-oncology. 2015-04-01
• Primary CNS lymphoma: a landmark trial and the next steps.
  Neuwelt EA, Schiff D> ;Neurology. 2015-03-24
• Much debated controversies of diffuse low-grade gliomas.
  Zadeh G, Khan OH, Vogelbaum M, Schiff D> ;Neuro-oncology. 2015-03-01
• Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma.
  Schiff D, Kesari S, de Groot J, Mikkelsen T, Drappatz J, Coyle T, Fichtel L, Silver B, Walters I, Reardon D> ;Invest New Drugs. 2015-02-01
• Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas.
  Norden AD, Schiff D, Ahluwalia MS, Lesser GJ, Nayak L, Lee EQ, Rinne ML, Muzikansky A, Dietrich J, Purow B, Doherty LM, LaFrankie DC, Pulverenti JR, Rifenburg JA, Rula...> ;J. Neurooncol.. 2015-01-01
• Join now to see all